< Practice Enhancement Programs / PAH QUERI
Study Title:
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative  (PAH QuERI)

Status: closed to patient enrollment

FDA Clinical Trial number:
Not registered with clinicaltrials.gov (sponsor's decision)

Brief description:  
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative  (PAH QuERI) represents an  innovative integration of guidelines and clinical care delivery aimed to identify and implement evidence based practices in routine health care setting.

PAH QuERI is a multicenter, observational study targeting patients with suspected or confirmed Pulmonary Arterial Hypertension (WHO Group I etiological classification

The purpose of this initiative is to facilitate access to  published PAH guidelines by participating physicians and to allow them an opportunity of evaluating the applicability of the guidelines to their practice and ability to adhere to the guidelines as part of their patient management.  The electronic case report form, which physicians will be asked to complete, will provide a platform for diagnostic and therapeutic work up of PAH patients, prompting participating physicians to follow the guidelines. Integration of this approach into physician’s work environment will provide opportunities to apply the standard of care.

To access the PAH QuERI website you must be a registered
user and you must log on.

Eligibility:  
previously diagnosed, newly diagnosed or suspected patients with Pulmonary Arterial Hypertension

Inclusion criteria:
a) Symptoms consistent with PAH (exertional dyspnea, fatigue or weakness, syncope or exertional presyncope, angina, peripheral edema, abdominal distension0
b)  At risk for PAH (first degree relative with idiopathic PAH, known genetic mutation, scleroderma spectrum of disease, congenital systemic-to-pulmonary shunt, portal hypertension, other with high risk of suspicion)
c) Consent

Exclusion criteria:
Unavailable for follow up

Sponsor(s):
Actelion Inc.